当前位置: X-MOL 学术Tuberculosis › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A multi-targeting pre-clinical candidate against drug-resistant tuberculosis
Tuberculosis ( IF 2.8 ) Pub Date : 2021-06-18 , DOI: 10.1016/j.tube.2021.102104
Parvinder Kaur 1 , Vijay Potluri 1 , Vijay Kamal Ahuja 1 , C N Naveenkumar 1 , Ramya Vadageri Krishnamurthy 1 , Shruthi Thimmalapura Gangadharaiah 2 , Prasad Shivarudraiah 2 , Sumesh Eswaran 2 , Christy Rosaline Nirmal 3 , Balasubramanian Mahizhaveni 3 , Azger Dusthackeer 3 , Rajesh Mondal 3 , Sarah M Batt 4 , Emily J Richardson 4 , Nicholas J Loman 4 , Gurdyal Singh Besra 4 , Radha Krishan Shandil 1 , Shridhar Narayanan 1
Affiliation  

FNDR-20081 [4-{4-[5-(4-Isopropyl-phenyl)- [1,2,4]oxadiazol-3-ylmethyl]-piperazin-1-yl}-7-pyridin-3-yl-quinoline] is a novel, first in class anti-tubercular pre-clinical candidate against sensitive and drug-resistant Mycobacterium tuberculosis (Mtb). In-vitro combination studies of FNDR-20081 with first- and second-line drugs exhibited no antagonism, suggesting its compatibility for developing new combination-regimens. FNDR-20081, which is non-toxic with no CYP3A4 liability, demonstrated exposure-dependent killing of replicating-Mtb, as well as the non-replicating-Mtb, and efficacy in a mouse model of infection. Whole genome sequencing (WGS) of FNDR-20081 resistant mutants revealed the identification of pleotropic targets: marR (Rv0678), a regulator of MmpL5, a transporter/efflux pump mechanism for drug resistance; and Rv3683, a putative metalloprotease potentially involved in peptidoglycan biosynthesis. In summary, FNDR-20081 is a promising first in class compound with the potential to form a new combination regimen for MDR-TB treatment.



中文翻译:

一种针对耐药结核病的多靶向临床前候选药物

FNDR-20081 [4-{4-[5-(4-异丙基-苯基)-[1,2,4]恶二唑-3-基甲基]-哌嗪-1-基}-7-吡啶-3-基-喹啉] 是一种新型的、一流的抗结核病临床前候选药物,可对抗敏感和耐药结核分枝杆菌(Mtb)。FNDR-20081 与一线和二线药物的体外联合研究没有显示出拮抗作用,表明它与开发新的联合方案具有相容性。FNDR-20081 无毒且无 CYP3A4 责任,在小鼠感染模型中表现出暴露依赖性杀死复制型 Mtb 以及非复制型 Mtb 和功效。FNDR-20081 抗性突变体的全基因组测序 (WGS) 揭示了多效性靶标的鉴定:marR(Rv0678),一种 MmpL5 的调节剂,一种用于耐药性的转运蛋白/外排泵机制;和 Rv3683,一种推定的金属蛋白酶,可能参与肽聚糖的生物合成。总之,FNDR-20081 是一种很有前途的一流化合物,有可能形成一种新的耐多药结核病联合治疗方案。

更新日期:2021-06-29
down
wechat
bug